

Pulmonary Arterial Hypertension (PAH)

Sildenafil tablet (generic Revatio)
Tadalafil tablet (generic Adcirca, Alyq)
Ambrisentan tablet (generic Letairis)
Bosentan tablet & tablet for oral susp) (generic Tracleer)
Opsumit tablet (macitentan)
Epoprostenol injection (generic Flolan and Veletri)
Treprostinil injection IV or SC (generic Remodulin)
Veletri (epoprostenol) injection
Orenitram (treprostinil) extended-release tablets and titration packs
Uptravi (selexipag) tablet
Winrevair (sotatercept-csrk) SC injection

POLICY

I. CRITERIA FOR INITIAL APPROVAL

Authorization of 6 months may be granted for treatment of PAH when all the following criteria are met:

- A. Prescriber is either one of the following:
 - a. Prescriber is associated with an accredited Center of Comprehensive Care by the Pulmonary Hypertension Association for adult members
 - b. Prescriber is a cardiologist, pulmonologist or physician specializing in PAH for pediatric members
- B. Documentation that the member has PAH defined as WHO Group 1 class of pulmonary hypertension (refer to Appendix)
- C. PAH was confirmed and member has documentation of by either criterion (1) or criterion (2) below:
 1. Right heart catheterization with documentation of all of the following results:
 - i. Mean pulmonary arterial pressure (mPAP) > 20mmHg
 - ii. Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
 - iii. Pulmonary vascular resistance (PVR) > 2 Wood units in adult members or pulmonary vascular resistance index (PVRI) ≥ 3 Wood units x m² in pediatric members
 - a. For Winrevair requests ONLY, pulmonary vascular resistance (PVR) ≥ 5 Wood units while stable on at least 2 PAH medications
 2. For infants less than one year of age with any of the following conditions, documentation that the PAH was confirmed by Doppler echocardiogram if right heart catheterization cannot be performed.
- D. With the exception of members presenting in NYHA functional class IV, documentation that the member has undergone acute vasoreactivity testing and whether or not the results were positive; for those members who demonstrated a positive response to the acute vasoreactivity testing [defined as a fall in mean pulmonary arterial pressure (mPAP) of at least 10 mmHg to less than 40 mmHg with an increased or unchanged cardiac output], documentation must be submitted that PAH has progressed despite maximal medical treatment with a calcium channel blocker

Effective Date: 9/2017
Reviewed: 9/2017, 12/2018, 2/2019, 12/2019, 9/2020, 12/2021, 5/2022, 1/2023, 5/2023, 2/2024, 8/2024, 1/2025, 1/2026
Scope: Medicaid

- E. Dose and dosing regimen prescribed as well as medication therapy regimen is within FDA-approved guidelines and clinical guidelines
- F. If requesting bosentan tablets for oral suspension, documentation of medical rationale must be submitted for the reason why the member is unable to trial bosentan tablets.
- G. If requesting Winrevair, the member has documentation of all of the following criteria:
 - i. Member has WHO Functional Class II or III symptoms
 - ii. Member has a platelet count $\geq 50,000/\text{mm}^3$
 - iii. Member is currently receiving at least two other PAH therapies from two different pharmacological classes for ≥ 60 days:
 - a. Phosphodiesterase type 5 inhibitors (PDE5i) [e.g., sildenafil, tadalafil]
 - b. Endothelin receptor antagonists (ERAs) [e.g., ambrisentan, bosentan, Opsumit]
 - c. Soluble guanylate cyclase stimulator (sGCs) [e.g., Adempas]
 - d. Prostacyclins (e.g., Flolan, Orenitram, Remodulin, Tyvaso, Veletri, Ventavis, Upravi)
 - iv. Winrevair will be used as add-on therapy and current PAH background therapies will be continued (e.g. ERA, PDE5i) unless not tolerated after addition of Winrevair

II. CONTINUATION OF THERAPY

Authorization for 6 months may be granted for members with documentation of PAH who have documentation of improved outcomes (e.g., sustained increase in six-minute walk distance from baseline, improvement in PAH symptoms/functional class, has not experienced clinical deterioration) with requested therapy.

III. QUANTITY LIMITS

- A. Sildenafil 20mg tablet – 12 tablets per day
- B. Tadalafil 20mg tablet – 2 tablets per day
- C. Ambrisentan 5mg and 10mg tablets – 1 tablet per day
- D. Bosentan
 - a. 62.5mg tablet and 125mg tablet – 2 tablets per day
 - b. 32mg tablet for oral susp – 4 tablets per day
- E. Opsumit 10mg tablet – 1 tablet per day
- F. Upravi – 2 tablets per day for all strengths except for titration pack (1 pack of 200 tablets per 30 days)
- G. Winrevair – 1 kit per 21 days (daily dose of 0.05)

IV. APPENDIX

WHO Classification of Pulmonary Hypertension

1 PAH

- 1.1 Idiopathic (PAH)
- 1.2 Heritable PAH
- 1.3 Drug- and toxin-induced PAH
- 1.4. PAH associated with:
 - 1.4.1 Connective tissue diseases
 - 1.4.2 HIV infection
 - 1.4.3 Portal hypertension
 - 1.4.4 Congenital heart diseases
 - 1.4.5 Schistosomiasis
- 1.5 PAH long-term responders to calcium channel blockers
- 1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement
- 1.7 Persistent PH of the newborn syndrome

2 PH due to left heart disease

- 2.1 PH due to heart failure with preserved LVEF
- 2.2 PH due to heart failure with reduced LVEF
- 2.3 Valvular heart disease
- 2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH

3 PH due to lung diseases and/or hypoxia

- 3.1 Obstructive lung disease
- 3.2 Restrictive lung disease
- 3.3 Other lung disease with mixed restrictive/obstructive pattern
- 3.4 Hypoxia without lung disease
- 3.5 Developmental lung disorders

4 PH due to pulmonary artery obstruction

- 4.1 Chronic thromboembolic PH
- 4.2 Other pulmonary artery obstructions
 - 4.2.1 Sarcoma (high or intermediate grade) or angiosarcoma
 - 4.2.2 Other malignant tumors
 - Renal carcinoma
 - Uterine carcinoma
 - Germ cell tumours of the testis
 - Other tumours
 - 4.2.3 Non-malignant tumours
 - Uterine leiomyoma
 - 4.2.4 Arteritis without connective tissue disease
 - 4.2.5 Congenital pulmonary artery stenosis
 - 4.2.6 Parasites Hydatidosis

5 PH with unclear and/or multifactorial mechanisms

- 5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders
- 5.2 Systemic and metabolic disorders: Pulmonary Langerhans cell histiocytosis, Gaucher disease, glycogen storage disease, neurofibromatosis, sarcoidosis
- 5.3 Others: chronic renal failure with or without hemodialysis, fibrosing mediastinitis
- 5.4 Complex congenital heart disease

V. REFERENCES

1. Revatio prescribing information. Pfizer. January 2023.
2. Adcirca prescribing information. Eli Lilly and Company. December 2025.
3. Letairis prescribing information. Gilead. August 2025.
4. Tracleer prescribing information. Actelion. November 2025.
5. Opsumit prescribing information. Actelion Pharmaceuticals, Inc. April 2025.
6. Adempas prescribing information. Bayer HealthCare. June 2025.
7. Orenitram prescribing information. United Therapeutics Corp. November 2024.
8. Ventavis Prescribing Information. Actelion. March 2022.
9. Uptravi Prescribing Information. Actelion. July 2024 .
10. Veletri Prescribing Information. Actelion. November 2022.
11. Remodulin Prescribing Information. United Therapeutics Corp. July 2025.
12. Winrevair subcutaneous injection prescribing information. Merck. December 2025.
13. Hoepfer MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med.* 2023;388(16):1478-1490. doi: 10.1056/NEJMoa2213558
14. Hoepfer MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. Supplementary appendix. *N Engl J Med.* 2023;Suppl Appendix.
15. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. *Eur Respir J.* 2019;53(1):1802148. doi: 10.1183/13993003.02148-2018
16. Acceleron Pharma, Inc. A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [4/25/2024]. Available from: <https://clinicaltrials.gov/study/NCT04576988>. NLM Identifier: NCT04576988.
17. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension. A review. *JAMA.* 2022;327(14):1379-1391.
18. Humbert M, Kovacs G, Hoepfer MM, et al, for the ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.* 2022;43(38):3618-3731.
19. Maron B. Revised definition of pulmonary hypertension and approach to management: a clinical primer. *J Am Heart Assoc.* 2023 April 7. [epub ahead of print].
20. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults. Update of the CHEST guideline and Expert Panel Report. *CHEST.* 2019;155(3):565